Amyloidosis is a heterogeneous disease that results from the deposition of abnormal protein aggregates in various tissues and organs. The treatment and diagnosis of amyloidosis remain a challenge, and experts agree that there are several unmet needs in the field. In recent years, there have been advances in clinical trials investigating novel treatment approaches for amyloidosis, providing patients with more hope.

In this exclusive podcast, Angela Dispenzieri, MD, Mayo Clinic, Rochester, MN, shares some insights into the treatment and management of light chain (AL) amyloidosis, highlighting the importance of early diagnosis and raising awareness of this disease. Dr Dispenzieri also discusses important clinical trials, unmet needs and challenges in the field, and the promise of novel agents being evaluated for the treatment of this disease.

The post Addressing unmet needs and future treatment approaches in AL amyloidosis appeared first on VJHemOnc.